Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ASH 2014: Chimeric antigen receptor T cells shows promise in lymphoma

Written by | 19 Dec 2014

by Thomas R. Collins: The use of chimeric antigen receptor T-cells — in which a patient’s own T cells are modified to fight cancer cells — is showing good results… read more.

ASH 2014 Video Interview by Esther Drain: Hodgkin Lymphoma: Prognosis and Therapy. Professor Ajay Gopal (University of Washington) discusses where we are with prognostic biomarkers and interim PET scans to direct therapy in HL

Written by | 18 Dec 2014

by Thomas R. Collins: Pursuit of useful risk biomarkers in HL still a work-in-progress. The quest for biomarkers in classic Hodgkin lymphoma, to determine which patients are at a… read more.

ASH 2014 Video Interview by Esther Drain: Practice Changing News from ASH with Stephen Ansel, John Sweetenham & Ajay Gopal

Written by | 18 Dec 2014

Professor Stephen Ansell, Mayo Clinic, Rochester, MN, USA.  Professor John Sweetenham, Hunstman Cancer Institute, Saltlake City, USA.  Professor Ajay Gopal, University of Washington, WA, USA.

Team finds drug repurposing signal in e-health records

Written by | 3 Dec 2014

With research and development costs for many drugs reaching well into the billions, pharmaceutical companies want more than ever to determine whether their drugs already at market have… read more.

ESMO 2014 Report: FOLFIRI plus cetuximab in patients with liver-limited or non-liverlimited RAS wild-type metastatic disease

Written by | 24 Nov 2014

by Esther Drain:  A sub-group analysis of the CRYSTAL study.  In the CRYSTAL study, adding cetuximab (cet) to first-line chemotherapy (CT) improved clinical outcome in patients (pts) with RAS… read more.

ESMO 2014 Report: Special symposium on ‘Advances in precision medicine of metastatic colorectal cancer’

Written by | 21 Nov 2014

by Denys Wheatley: There is some irony in the title of this symposium because medicine should always be as precise as it can, and advances are expected that… read more.

ESMO 2014 Report: Adolescent and young adult cancer patients

Written by | 20 Nov 2014

Engagement of patients and understanding of early death in this group by Denys Wheatley. (1) When and why do teenage and young adult oncology patients die early in… read more.

ESMO 2014 Report: Reclassifying cancer through genomics

Written by | 19 Nov 2014

Keynote lecture: Professor Sir Mike Stratton (Cambridge/Hinxton, UK) by Denys Wheatley.  On the thesis that the genetic understanding of cancer is fundamental to classifying and hence treating patients… read more.

ESMO 2014 Report: Video interview with Professor Volker Heinemann (Munich) and other delegate views.

Written by | 14 Nov 2014

Click ‘Read More’ for the new data delegate views on whether early tumour shrinkage is now an accepted marker in mCRC.

ESMO 2014: Poster Session: REBECCA

Written by | 12 Nov 2014

by Denys Wheatley: A large cohort study of Regorafenib (REG) in the real-life setting in patients previously treated for metastatic colorectal cancer

ESMO 2014: Poster Session: MOSAIC study – Actualization of overall survival with a 10-year follow up and evaluation of BRAF (GREGOR investigators)

Written by | 11 Nov 2014

by Denys Wheatley: The session dealt primarily with the advanced (stage 2 and 3) colon cancer patients who had undergone resection, in a study discussed by Thiery Andre… read more.

ESMO 2014 Report: Precision medicine: Panacea or false dawn?

Written by | 6 Nov 2014

Reports from the European Society for Medical Oncology 2014 Congress in Madrid by Denys Wheatley:  In his talk on Visualising the true spectrum of cancer- will we get… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.